Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 2, 2013, Pages

  Horsburgh, C R ^a   Haxaire Theeuwes, M ^b   Lienhardt, C ^c   Wingfield, C ^d   McNeeley, D ^e   Pyne Mercier, L ^f   Keshavjee, S ^g   Varaine, F ^h  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b Tibotec   (Belgium)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d Path   (United States)

^e Medical Service Corporation International   (United States)

^f BILL AND MELINDA GATES FOUNDATION   (United States)

^g PARTNERS IN HEALTH   (United States)

^h MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Expanded access program; Import waiver; Open enrollment trial; Pre approval access; Pre marketing access

Indexed keywords

ISONIAZID; NEW DRUG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; COMPASSIONATE USE; DRUG APPROVAL; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STANDARD;

EID: 84872296080     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0017     Document Type: Review

References (34)

1. World Health Organization. Multidrug- and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO, 2010.
2. World Health Organization. Global tuberculosis report 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
3. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
4. Tahaoǧlu K, Toeruen T, Sevim T, et al. The treatment of multi-drug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
5. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128. (Pubitemid 36056718)
6. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326. (Pubitemid 40139109)
7. Chan E D, Laurel V, Strand M J, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109. (Pubitemid 38624789)
8. Dalton T, Cegielski P, Akkslip S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380: 1406-1417.
9. Mitnick C D, Shin S S, Seung K J, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
10. Keshavjee S, Gelmanova I Y, Farmer P E, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372: 1403-1409.
11. Jacobson K R, Tierney D B, Jeon C Y, Mitnick C D, Murray M B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
12. Médecins Sans Frontières/Partners in Health/Treatment Action Group. An evaluation of drug-resistant TB treatment scale-up. MSF/PIH/TAF, 2011. http://69.7.74.112/uploadedFiles/DRTB-Report-A4-Final.pdf Accessed August 2012.
13. World Health Organization, Stop TB Partnership. The Global Plan to Stop TB: 2011-2015. Geneva, Switzerland: WHO, 2010. http://www.stoptb.org/global/ plan/ Accessed August 2012.
14. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205 (Suppl 2): S241-S249.
15. Working Group on New TB Drugs, Stop TB Partnership, World Health Organization. TB drug pipeline. Geneva, Switzerland: WHO, 2012. http://www.newtbdrugs.org/pipeline. php Accessed August 2012.
16. Institute of Medicine. Expanding access to investigational therapies for HIV infection and AIDS. Roundtable for the development of drugs and vaccines against AIDS. Washington DC, USA: National Academy Press, 1991.
17. Vale J. Expanding expanded access: how the Food and Drug Administration can achieve better access to experimental drugs for seriously ill patients. Georgetown Law J 2008; 96: 2143-2175.
18. O'Brien R J, Geiter L J, Lyle M A. Rifabutin (ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex. Am Rev Respir Dis 1990; 141: 821-826. (Pubitemid 20157704)
19. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
20. Pineda J A, Pérez-Elías M J, Peña J M, Luque I, Rodríguez-Alcantara F; Fosamprenavir Expanded Access Program Group. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens. HIV Clin Trials 2008; 9: 309-313.
21. de Mendoza C, Martín-Carbonero L, Barreiro P, et al. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials 2002; 3: 304-309. (Pubitemid 34830681)
22. Compassionate use and treatment IND programs. Crit Path AIDS Proj 1996; 31: 40-67.
23. Amorosa V, Tebas P. Is it time to rethink the expanded-access programs for HIV infection? J Infect Dis 2007; 196: 974-977. (Pubitemid 47580288)
24. European Medicines Agency. Questions and answers on the compassionate use of medicines in the European Union. EMA/72144/2006(rev). London, UK: EMA, 2010.
25. British Columbia Cancer Agency. Guidelines for expanded access protocols. Vancouver, BC, Canada: BCCA Research Ethics Board, 2005. http://www.bccancer. bc.ca/NR/rdonlyres/3BDE5649-ACA6-40C3-B20E-FC09815C5D3F/9402/ EAPGuidelines2005Mar12.pdf Accessed August 2012.
26. Douglas N. Preapproval opportunities. Appl Clin Trials 2008; June 1. http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/ articleDetail.jsp?id=522052&pageID=1&sk=&date=3 Accessed October 2012.
27. O'Donnell M R, Padayatchi N, Master I, Osburn G, Horsburgh C R. Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis 2009; 13: 855-861.
28. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375: 1798-1807.
29. Moran M, Strub-Wourgaft N, Guzman J, Boulet P, Wu L, Pecoul B. Registering new drugs for low-income countries: the African challenge. PLoS Med 2011; 8: e1000411.
30. Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis: critical steps for prevention and control. N Engl J Med 2010; 363: 1050-1058.
31. World Health Organization. Guidance on ethics of tuberculosis prevention, care and control. WHO/HTM/TB/2010.16. Geneva, Switzerland: WHO, 2010.
32. Coleman C H, Jaramillo E, Reis A, Selgelid M. Guidance on ethics of tuberculosis prevention, care and control. Geneva, Switzerland: World Health Organization, 2010.
33. van Roey J, Haxaire M. The need to reform current drug registration processes to improve access to essential medicines in developing countries. Pharm Med 2008; 22: 207-213.
34. Ndomondo-Sigonda M, Ambali A. The African medicines regulatory harmonization initiative: rationale and benefits. Clin Pharmacol Ther 2011; 89: 176-179.